CytoDyn Announces Productive Pre-BLA Meeting with FDA for PRO 140 Combination Therapy
Rolling BLA Submission Starting as Early as the End of 2018 - FDA Provides Guidance on Ongoing Requirements VANCOUVER, Washington, ...
Home » PRO 140
Rolling BLA Submission Starting as Early as the End of 2018 - FDA Provides Guidance on Ongoing Requirements VANCOUVER, Washington, ...
Data Provide Support for PRO 140 as long-acting, HIV-1 maintenance therapy VANCOUVER, Washington, May 24, 2018 (GLOBE NEWSWIRE) -- CytoDyn ...
VANCOUVER, Washington, Oct. 05, 2017, CYDY, (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB:CYDY), a biotechnology company focused on the development of new antibody ...
VANCOUVER, Washington, Aug. 21, 2017, CYDY, (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB:CYDY), a biotechnology company focused on the development of new antibody ...
VANCOUVER, Washington, Jan. 11, 2017, CYDY, (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB:CYDY), a biotechnology company focused on the development of ...